Global Vaccine Demand And Specialty Medicines Will Expand Future Opportunities

Key Takeaways

• Robust growth in vaccines and specialty medicines, alongside innovation in oncology and immunology, positions GSK for sustained revenue and margin expansion.
  
• Diversification, operational efficiencies, and accelerated R&D enhance resilience, supporting strong long-term sales and earnings potential despite industry pressures.
  
• Patent expiries, pricing pressure, legal liabilities, stagnating core segments, and high-risk R&D threaten GSK's ability to offset revenue loss and maintain earnings growth.

Catalysts

Engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.

• GSK is well-positioned to benefit from the global rise in demand for vaccines and specialty medicines, driven by an aging population and higher healthcare access in emerging markets-evidenced by robust ongoing growth in Shingrix, meningitis vaccines, and double-digit expansion in specialty medicines-which supports sustained revenue growth and greater resilience in future cash flows.
  
• Strong volume growth in key high-margin areas like oncology (Jemperli, Blenrep), immunology (Benlysta, Nucala, depemokimab), and HIV (long-acting injectables) demonstrates GSK's ability to capture premium pricing and leverage long-term trends toward innovative, biologic, and personalized therapies, positively impacting future earnings and supporting margin expansion as these portfolios scale.
  
• Strategic R&D investments and business development (multiple Phase III starts, advanced modality deals, new manufacturing capacity, and collaborations such as with Hengrui) are accelerating pipeline momentum, with expectations for meaningful late-stage readouts and new launches through 2026 and beyond, increasing the visibility and durability of future revenue growth.
  
• Ongoing operational improvements, including cost efficiencies post-Haleon spin-off, SG&A productivity initiatives, and supply chain optimization (with a shift toward U.S. manufacturing), are enhancing net margins and underpinning stronger long-term free cash flow, enabling reinvestment and greater shareholder returns.
  
• GSK's diversification across vaccines, specialty medicines, and geographic markets positions the company to mitigate pressures from drug price controls and competitive threats, while large, unmet needs in chronic and infectious diseases (COPD, hepatitis, UTIs, HIV) provide a long-term runway for growth, supporting confidence in its medium
• and long-term sales and earnings outlook.

GSK Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming GSK's revenue will grow by 4.3% annually over the next 3 years.
• Analysts assume that profit margins will increase from 10.8% today to 18.8% in 3 years time.
• Analysts expect earnings to reach £6.7 billion (and earnings per share of £1.71) by about August 2028, up from £3.4 billion today. The analysts are largely in agreement about this estimate.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 11.7x on those 2028 earnings, down from 16.2x today. This future PE is lower than the current PE for the US Pharmaceuticals industry at 28.1x.
• Analysts expect the number of shares outstanding to decline by 0.78% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.82%, as per the Simply Wall St company report.

GSK Future Earnings Per Share Growth

Risks

• Loss of exclusivity (LOE) for key drugs, notably dolutegravir in HIV and respiratory products, is flagged as a future revenue risk-management guidance and analyst questions indicate patent expiries post-2028 could hit earnings and net margins, especially if new launches like Blenrep face timing risks or fail to compensate for these losses.
  
• GSK faces rising pricing and regulatory headwinds, including Medicare Part D redesign and increasing governmental scrutiny on drug pricing and tariffs in the U.S. and Europe. These could structurally erode revenue growth and pressure net margins over the long term, especially given the repeated reference to pricing headwinds and assumptions of future mitigation actions.
  
• Legal risks from legacy issues, specifically significant Zantac litigation payments (noted as £1.1 billion expected in H2 and nearly £3 billion in total outflows for Zantac and other settlements), are directly reducing cash flow and increasing net debt, with further negative implications for reinvestment, R&D, and shareholder returns if unresolved.
  
• The vaccines and general medicines segments are facing either flattening or outright declining sales due to tough comparators, generic competition, and slower-than-expected recovery in key markets such as China. This stagnation limits overall revenue growth and offsets gains in specialty medicines.
  
• Although GSK is making large R&D investments and expanding its pipeline, the text notes the risk of escalating R&D costs with uncertainty around the probability of converting late-stage programs into commercial blockbusters. This risk is heightened by increasing industry competition in areas like oncology and immunology, raising the chance of underwhelming returns on R&D and constraining long-term earnings growth.

Valuation

• The analysts have a consensus price target of £16.422 for GSK based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of £25.2, and the most bearish reporting a price target of just £11.2.
  
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be £35.9 billion, earnings will come to £6.7 billion, and it would be trading on a PE ratio of 11.7x, assuming you use a discount rate of 6.8%.
  
• Given the current share price of £13.73, the analyst price target of £16.42 is 16.4% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.